KemPharm Inc (NASDAQ:KMPH) has been given an average recommendation of “Buy” by the nine brokerages that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $11.40.
Several equities research analysts have weighed in on the company. Zacks Investment Research downgraded KemPharm from a “buy” rating to a “hold” rating in a report on Wednesday, November 21st. Oppenheimer set a $11.00 price target on KemPharm and gave the stock a “buy” rating in a report on Thursday, September 20th. Finally, CIBC reissued an “outperform” rating on shares of KemPharm in a report on Friday, September 21st.
Institutional investors have recently added to or reduced their stakes in the stock. Bridgeway Capital Management Inc. acquired a new stake in shares of KemPharm during the third quarter worth about $264,000. Millennium Management LLC lifted its holdings in shares of KemPharm by 878.0% during the second quarter. Millennium Management LLC now owns 151,250 shares of the specialty pharmaceutical company’s stock worth $983,000 after purchasing an additional 135,784 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of KemPharm by 101.1% during the second quarter. Renaissance Technologies LLC now owns 181,800 shares of the specialty pharmaceutical company’s stock worth $1,182,000 after purchasing an additional 91,400 shares during the period. Vanguard Group Inc. lifted its holdings in shares of KemPharm by 9.3% during the third quarter. Vanguard Group Inc. now owns 479,335 shares of the specialty pharmaceutical company’s stock worth $2,301,000 after purchasing an additional 40,700 shares during the period. Finally, Vanguard Group Inc lifted its holdings in shares of KemPharm by 9.3% during the third quarter. Vanguard Group Inc now owns 479,335 shares of the specialty pharmaceutical company’s stock worth $2,301,000 after purchasing an additional 40,700 shares during the period. 19.26% of the stock is owned by hedge funds and other institutional investors.
KemPharm (NASDAQ:KMPH) last issued its quarterly earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.17). Sell-side analysts forecast that KemPharm will post -3.19 EPS for the current year.
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.
Featured Article: What is Liquidity?
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.